Edwards Lifesciences Corporation (FRA:EWL)

Market Cap	39.74B -1.4%
Revenue (ttm)	5.01B +10.6%
Net Income	1.17B -67.1%
EPS	1.99 -66.2%
Shares Out	n/a
PE Ratio	34.09
Forward PE	28.89
Dividend	n/a
Ex-Dividend Date	n/a

Volume	200
Average Volume	47
Open	67.60
Previous Close	67.75
Day's Range	67.49 - 68.75
52-Week Range	59.49 - 74.98
Beta	n/a
RSI	37.69
Earnings Date	Feb 13, 2026

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. The company offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband brands. It also provides surgical structural heart solution...

• Industry: Orthopedic, Prosthetic, and Surgical Appliances and Supplies
• Founded: 1958
• Employees: 15,800
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: EWL

Financial Performance

In 2024, Edwards Lifesciences's revenue was $5.44 billion, an increase of 8.57% compared to the previous year's $5.01 billion. Earnings were $4.17 billion, an increase of 197.68%.

Financial numbers in USD